D-ribose is a simple sugar the body uses to rebuild depleted cellular energy. Its most consistent signals are modest gains in heart filling, quality of life, and reduced muscle soreness; fatigue and performance claims are weak. It lowers blood sugar and, as a highly reactive sugar, raises an unresolved long-term safety question. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting blood glucose | 75–90 mg/dL | Detects glucose lowering and reactive-hypoglycemia risk |
| HbA1c | < 5.4% | Tracks average blood sugar and glycemic control over ~3 months |
| Glycated albumin / fructosamine | Fructosamine ~200–230 μmol/L | Shorter-term glycation marker relevant to a highly glycating sugar |
| Uric acid | Men 3.5–6.0; women 3.0–5.5 mg/dL | Screens for purine-load effects in those prone to gout |
| eGFR / creatinine | eGFR > 90 mL/min/1.73m²; creatinine mid-normal | Confirms adequate kidney clearance of the sugar |
Cadence: Baseline, then recheck at 6–12 weeks and roughly every 6–12 months; more frequent glucose checks in the first weeks for anyone on glucose-lowering medication.